Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of duchenne muscular dystrophy

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Janssen, Paul M L ^a,c   Murray, Jason D ^a   Schill, Kevin E ^a   Rastogi, Neha ^a   Schultz, Eric J ^a   Tran, Tam ^b   Raman, Subha V ^b,c   Rafael Fortney, Jill A ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; IMMUNOGLOBULIN G; LISINOPRIL; LOSARTAN; PREDNISOLONE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; HEART FUNCTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE MASS; MUSCULOSKELETAL FUNCTION; NONHUMAN; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DIURETICS; DYSTROPHIN; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; LISINOPRIL; LOSARTAN; MALE; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; PREDNISOLONE; SPIRONOLACTONE; UTROPHIN;

EID: 84895804761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088360     Document Type: Article

References (33)

1. Goyenvalle A, Seto JT, Davies KE, Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20: R69-78.
2. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, et al. (2012) Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 45: 796-802.
3. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320: 1592-1597. (Pubitemid 19154573)
4. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
5. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, 3rd, et al. (1991) Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41: 1874-1877.
6. Machado DL, Silva EC, Resende MB, Carvalho CR, Zanoteli E, et al. (2012) Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy. BMC Res Notes 5: 435.
7. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, et al. (1983) Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 6: 91-103. (Pubitemid 13092078)
8. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, et al. (2013) The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 5.
9. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, et al. (2010) North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20: 712-716.
10. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41: 500-510.
11. Muntoni F (2003) Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 16: 577-583.
12. Sanyal SK, Johnson WW, Thapar MK, Pitner SE (1978) An ultrastructural basis for electrocardiographic alterations associated with Duchenne's progressive muscular dystrophy. Circulation 57: 1122-1129. (Pubitemid 8343629)
13. Hagenbuch SC, Gottliebson WM, Wansapura J, Mazur W, Fleck R, et al. (2010) Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol 105: 1451-1455.
14. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11: 463-471.
15. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, et al. (2011) Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124: 582-588.
16. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, et al. (2008) Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci 264: 106-111. (Pubitemid 350186318)
17. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81: 1189-1192. (Pubitemid 14171480)
18. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, et al. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580. (Pubitemid 19189735)
19. Murray JD, Canan BD, Martin CD, Stangland JE, Rastogi N, et al. (2012) The force-temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design. Front Physiol 3: 422.
20. Rodino-Klapac LR, Janssen PM, Montgomery CL, Coley BD, Chicoine LG, et al. (2007) A translational approach for limb vascular delivery of the microdystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med 5: 45.
21. Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, et al. (2009) Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild type mice. Am J Physiol Cell Physiol 296: C476-488.
22. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, et al. (2011) Peptide-Based Inhibition of NF-kappaB Rescues Diaphragm Muscle Contractile Dysfunction in a Murine Model of Duchenne Muscular Dystrophy. Mol Med 17: 508-515.
23. De Luca A (2012) Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol 31: 40-47.
24. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, et al. (2010) Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS One 5: e11220.
25. Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, et al. (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One 7: e34204.
26. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, et al. (2006) Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166: 1016-1020.
27. Payne JR, Kotwinski PJ, Montgomery HE (2004) Cardiac effects of anabolic steroids. Heart 90: 473-475. (Pubitemid 38530148)
28. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110: 3281-3288. (Pubitemid 39525078)
29. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, et al. (2011) Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 6: e20856.
30. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, et al. (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16: 87-95.
31. Janssen PML, Hiranandani N, Mays TA, Rafael-Fortney JA (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289: H2373-2378. (Pubitemid 41698545)
32. Beastrom N, Lu H, Macke A, Canan BD, Johnson EK, et al. (2011) mdx(5cv) Mice Manifest More Severe Muscle Dysfunction and Diaphragm Force Deficits than Do mdx Mice. Am J Pathol.
33. Chandrasekharan K, Yoon JH, Xu Y, Devries S, Camboni M, et al. (2010) A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy. Sci Transl Med 2: 42ra54.